Research Paper Volume 13, Issue 14 pp 18740—18756

Figure 8. MiR-106b-5p promotes proliferation and progression of lung cancer cells. (A) RT-qPCR analysis shows expression levels of miR-106b-5p in the human bronchial epithelial cell line, BEAS-2B, and LUAD cell lines, H1299, HCC827, A549 and PC9. (B) RT-qPCR analysis shows miR-106b-5p expression levels in H1299 and HCC827 cells transfected with negative control (NC) or miR-106b-5p inhibitor. (C) MTT assay shows proliferation status of H1299 and HCC827 cells transfected with negative control (NC) or miR-106b-5p inhibitor. (D) EdU assay results show proliferation status of H1299 and HCC827 cells transfected with negative control (NC) or miR-106b-5p inhibitor. (E) Colony formation assay shows the number of colonies formed by H1299 and HCC827 cells transfected with negative control (NC) or miR-106b-5p inhibitor. (F) Transwell assays show migration and invasion ability of H1299 and HCC827 cells transfected with negative control (NC) or miR-106b-5p inhibitor. Results are represented as means ± SD; ^*p < 0.05, ^**p < 0.01, and ^***p < 0.001 vs. control group.